Crossmark

Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia

Crossref DOI link: https://doi.org/10.1186/s12888-018-1856-y

Published Online: 2018-09-12

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Achtyes, Eric https://orcid.org/0000-0003-3128-2971
Simmons, Adam

Skabeev, Anna

Levy, Nikki

Jiang, Ying

Marcy, Patricia

Weiden, Peter J.
Funding

Funding for this research was provided by:

Alkermes, Inc.
License Information

Text and Data Mining valid from 2018-09-12
More Information

Article History

Received: 21 May 2018

Accepted: 21 August 2018

First Online: 12 September 2018

Ethics approval and consent to participate

: This survey was approved by the Northwell Health Institutional Review Board. Patients were given an information sheet describing the study and verbal informed consent was obtained from patients who agreed to complete the survey.

: Not applicable

: EA (MD), has received research support from Alkermes, AssurEx, Avanir, Boehringer Ingelheim, Janssen, Neurocrine Biosciences, Novartis, Otsuka, Pfizer, Pine Rest Foundation, Priority Health, Network180, and Vanguard Research Group and has served on advisory panels for Roche, Janssen, Neurocrine Biosciences and the Vanguard Research Group. PM is the executive director of the Vanguard Research Group, which has received research support from Otsuka, Alkermes, Lundbeck, and Janssen. PJW (MD), A Simmons (MPH), NL, and YJ (PhD), are employees of Alkermes, Inc. A Skabeev (MD), was employed by Alkermes at the time of the study.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.